Maytenus ilicifolia Mart. ex Reiss is a plant native to South America, popularly used in the treatment of gastric disorders. The increase in the consumption of herbal products associated with conventional medications demands attention for the potential risks of interactions. The aim of the study was to evaluate potential pharmacokinetic interactions due to coadministration of M. ilicifolia extracts with drug substrates of P-glycoprotein (P-gp) and cytochrome P450 3A4 isoform (CYP3A4). Five extracts of M. ilicifolia were prepared, and the contents of the main secondary metabolites were determined. A high-performance liquid chromatography (HPLC) method was developed for the simultaneous quantitation of midazolam, nifedipine, and their respective metabolites and applied to assess the potential of M. ilicifolia extracts on hepatic metabolism mediated by the CYP3A4 enzyme. The influence of the extracts on the intestinal permeability of fexofenadine was evaluated by determining P-gp activity, using a Caco-2 cell model. The extracts were characterized in terms of total phenolic (1.77–11.46%), tannin (1.67–3.36%), and flavonoid (0.21–2.64%). The hydroacetonic extract (HAE1) exhibited a remaining activity (%RA) of 50.1% for the 1-hydroxylation of midazolam and 40.1% for the oxidation of nifedipine, indicating moderate inhibition of CYP3A4. HAE1 reduced the fexofenadine efflux ratio to an extent similar to that of verapamil (IC50 = 20.42 μg/mL), suggesting an inhibitory effect on the P-gp activity. The extracts demonstrated the potential to inhibit both CYP3A4 and P-gp. Therefore, coadministration of M. ilicifolia-based preparations may potentially alter the pharmacokinetics of drugs that are substrates of these systems.
Fungal infections have become a growing concern in healthcare, particularly in immuno-compromised individuals, with species like Candida, Cryptococcus, and Sporothrix pos-ing significant challenges due to rising resistance and limited treatment options. In re-sponse, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve water solubility and pharmacokinetic properties. The com-pound demonstrated a broad antifungal spectrum, particularly effective against Crypto-coccus neoformans and Candida auris, with minimal irritant potential and low cytotoxi-city. RW3 showed favorable solubility and high intestinal permeability, indicating poten-tial for oral administration. The results suggest RW3 as a promising lead for further de-velopment as a therapeutic agent for systemic fungal infections. These findings under-score the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.
Fungal infections have become a growing concern in healthcare, particularly in immunocompromised individuals, with species like Candida, Cryptococcus, and Sporothrix posing significant challenges due to rising resistance and limited treatment options. In response, novel antifungal agents are being explored, including thiazolyl hydrazones. This study focuses on the development of a novel thiazolylhydrazone derivative, RW3. RW3 was synthesized to improve its water solubility and pharmacokinetic properties. The compound demonstrated a broad antifungal spectrum, particularly effective against Cryptococcus neoformans and Candida auris, with minimal irritant potential and low cytotoxicity. RW3 showed favorable solubility and high intestinal permeability, indicating potential for oral administration. The results suggest RW3 as a promising lead for further development as a therapeutic agent for systemic fungal infections. These findings underscore the importance of optimizing drug properties to enhance efficacy and safety profiles, opening the path for the development of innovative antifungal treatments.